Enantioselective inhibition of Cytochrome P450-mediated drug metabolism by a novel antithrombotic agent, S002-333: Major effect on CYP2B6
- 1 August 2016
- journal article
- Published by Elsevier in Chemico-Biological Interactions
- Vol. 256, 257-265
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- In vitrometabolism of a novel antithrombotic compound, S002-333, and its enantiomers: quantitative cytochrome P450 phenotyping, metabolic profiling and enzyme kinetic studiesXenobiotica, 2013
- Reliable High-throughput Method for Inhibition Assay of 8 Cytochrome P450 Isoforms Using Cocktail of Probe Substrates and Stable Isotope-labeled Internal StandardsDrug Metabolism and Pharmacokinetics, 2012
- Bioanalytical method development and validation for simultaneous estimation of (R)- and (S)-isomers of S002-333: a potent novel anti-thrombotic agent using LC–MS/MSMedicinal Chemistry Research, 2010
- New Antithrombotic DrugsClinical Pharmacology & Therapeutics, 2009
- New Antithrombotic DrugsChest, 2008
- Enantioselectivity of inhibition of cytochrome P450 3A4 (CYP3A4) by ketoconazole: Testosterone and methadone as substratesChirality, 2003
- High‐throughput cytochrome P450 (CYP) inhibition screening via a cassette probe‐dosing strategy. VI. Simultaneous evaluation of inhibition potential of drugs on human hepatic isozymes CYP2A6, 3A4, 2C9, 2D6 and 2E1Rapid Communications in Mass Spectrometry, 2001
- Potent inhibition of CYP2D6 by haloperidol metabolites: stereoselective inhibition by reduced haloperidolBritish Journal of Clinical Pharmacology, 2001
- The Safety of Newly Approved MedicinesJAMA, 1999
- Stereoselective inhibition of rat brain cyclooxygenase by dexketoprofenChirality, 1997